Premium
Progesterone inhibition in mid‐trimester termination of pregnancy: physiological and clinical effects
Author(s) -
SELINGER MARK,
MACKENZIE IAN Z.,
GILLMER MICHAEL D.,
PHIPPS SUE L.,
FERGUSON JANE
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb02325.x
Subject(s) - medicine , pregnancy , oxytocin , placebo , abortion , prostaglandin , obstetrics , clinical trial , prostaglandin e2 , anesthesia , biology , genetics , alternative medicine , pathology
Summary. A double‐blind, placebo controlled clinical trial was conducted to assess the clinical and physiological effects of‘epostane’, a progesterone synthesis inhibitor, in mid‐trimester prostaglandin termination of pregnancy. Mean peripheral progesterone levels had fallen by 74% after 72 h in the patients treated wtih epostane. The mean induction abortion interval in the treatment group was 490 (SD 271) min, compared with 1432 (SD 640) min in the control group. Intrauterine pressure recording demonstrated increased sensitivity to prostaglandin E2 after epostane treatment but no change in oxytocin sensitivity. The clinical implications of facilitated induction of abortion are discussed.